DVS Sciences

About:

DVS Sciences develops bioanalytical solutions for use in biomarker discovery, biological research and clinical applications.

Website: http://www.dvssciences.com

Top Investors: Pfizer Venture Investments, 5AM Ventures, Mohr Davidow Ventures, Roche Finance

Description:

DVS Sciences, Inc. manufactures and has global distribution of novel bioanalytical solutions for use in biomarker discovery, biological research and possible clinical applications. The patented multi-parameter solution comprises a high-throughput mass cytometer for quantitative individual cell analysis, CyTOF®, and a suite of MAXPAR® reagents, which include stable-isotope-tagged antibodies. The CyTOF – MAXPAR system overcomes the limitations of conventional flow cytometry, simplifies sample preparation and simultaneously identifies up to 100 biomarkers with high resolution and wide dynamic range. CyTOF systems are installed in leading laboratories across the U.S., Canada and Asia.

Total Funding Amount:

$14.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Sunnyvale, California, United States

Founded Date:

2004-01-01

Founders:

Olga Ornatsky, Scott Tanner, Vladimir Baranov

Number of Employees:

11-50

Last Funding Date:

2011-07-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai